Physician profile
Wayne Little
NPI 1508854456
$928.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $107.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.45 | 2019-2020 | |
| Amgen INC. | $272.19 | 2019-2020 | |
| Pfizer INC. | $107.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.25 | 2019 | |
| Lilly USA, LLC | $44.29 | 2019 | |
| Astellas Pharma US INC | $27.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.36 | 2020 | |
| Amarin Pharma, INC. | $16.61 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.36 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.71 | 2020 | |
| Nevro Corp. | $12.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.